CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...
Phase 2
Chicago, Illinois, United States and 43 other locations
to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung...
Phase 2
Hinsdale, Illinois, United States and 116 other locations
with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....
Phase 3
Chicago, Illinois, United States and 209 other locations
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...
Phase 2
Chicago, Illinois, United States and 52 other locations
in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung...
Phase 1, Phase 2
Chicago, Illinois, United States and 48 other locations
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...
Phase 2
Chicago, Illinois, United States and 123 other locations
N2) NSCLC (per the 8th International Association for the Study of Lung Cancer classification). The primary objective of this study ...
Phase 2
Chicago, Illinois, United States and 8 other locations
with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung ...
Phase 3
Niles, Illinois, United States and 210 other locations
Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study...
Phase 2
Chicago, Illinois, United States and 46 other locations
results observed in participants with Extensive-stage Small Cell Lung Cancer (ES-SCLC) who received at least 1 prior line of platin...
Phase 2
Chicago, Illinois, United States and 55 other locations
Clinical trials
Research sites
Resources
Legal